| 1 |
Stehlik J, Kobashigawa J, Hunt SA, et al. Honoring 50 years of clinical heart transplantation in circulation: In-depth state-of-the-art review[J]. Circulation, 2018, 137(1): 71-87.
|
| 2 |
Zaza G, Granata S, Caletti C, et al. mTOR inhibition role in cellular mechanisms[J]. Transplantation, 2018, 102(2S Suppl 1): S3-S16.
|
| 3 |
Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease[J]. Cell, 2017, 168(6): 960-976.
|
| 4 |
Xie A, Yan H, Fu J, et al. T follicular helper and memory cell responses and the mTOR pathway in murine heart transplantation[J]. J Heart Lung Transplant, 2020, 39(2): 134-144.
|
| 5 |
Fine NM, Kushwaha SS. Recent advances in mammalian target of rapamycin inhibitor use in heart and lung transplantation[J]. Transplantation, 2016, 100(12): 2558-2568.
|
| 6 |
Jennings DL, Lange N, Shullo M, et al. Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis[J]. Int J Cardiol, 2018, 265:71-76.
|
| 7 |
Heble A, Everitt MD, Gralla J, et al. Safety of mTOR inhibitor continuation in pediatric heart transplant recipients undergoing surgical procedures[J]. Pediatr Transplant, 2018, 22(1).
|
| 8 |
Asleh R, Briasoulis A, Kremers WK, et al. Long-term sirolimus for primary immunosuppression in heart transplant recipients[J]. J Am Coll Cardiol, 2018, 71(6): 636-650.
|
| 9 |
Ueyama H, Kuno T, Takagi H, et al. Maintenance immunosuppression in heart transplantation: insights from network meta-analysis of various immunosuppression regimens[J]. Heart Fail Rev, 2020.
|
| 10 |
Rossano JW, Jefferies JL, Pahl E, et al. Use of sirolimus in pediatric heart transplant patients: A multi-institutional study from the Pediatric Heart Transplant Study Group[J]. J Heart Lung Transplant, 2017, 36(4): 427-433.
|
| 11 |
Asleh R, Clavell AL, Pereira NL, et al. Incidence of malignancies in patients treated with sirolimus following heart transplantation[J]. J Am Coll Cardiol, 2019, 73(21): 2676-2688.
|
| 12 |
Barten MJ, Hirt SW, Garbade J, et al. Comparing everolimus-based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from six months after heart transplantation: the randomized MANDELA study[J]. Am J Transplant, 2019.
|
| 13 |
Asleh R, Alnsasra H, Lerman A, et al. Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients[J]. Am J Transplant, 2021, 21(2): 626-635.
|
| 14 |
Mallah SI, Atallah B, Moustafa F, et al. Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy[J]. Prog Cardiovasc Dis, 2020, 63(3): 194-209.
|
| 15 |
Lee MS, Tadwalkar RV, Fearon WF, et al. Cardiac allograft vasculopathy: A review[J]. Catheter Cardiovasc Interv, 2018, 92(7): E527-E536.
|
| 16 |
Lund LH, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third adult heart transplantation report-2016; Focus theme: Primary diagnostic indications for transplant[J]. J Heart Lung Transplant, 2016, 35(10): 1158-1169.
|
| 17 |
Chih S, Chong AY, Mielniczuk LM, et al. Allograft vasculopathy: The achilles′ heel of heart transplantation[J]. J Am Coll Cardiol, 2016, 68(1): 80-91.
|
| 18 |
Nikolova AP, Kobashigawa JA. Cardiac allograft vasculopathy[J]. Transplantation, 2019, 103(7): 1338-1348.
|
| 19 |
Sobieszczanska-Malek M, Korewicki J, Komuda K, et al. Heart transplantation and risk of cardiac vasculopathy development: What factors are important？[J]. Ann Transplant, 2017, 22:682-688.
|
| 20 |
Johansson I, Andersson R, Friman V, et al. Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients[J]. BMC Infect Dis, 2015, 15:582.
|
| 21 |
Klimczak-Tomaniak D, Roest S, Brugts JJ, et al. The association between cytomegalovirus infection and cardiac allograft vasculopathy in the era of antiviral valganciclovir prophylaxis[J]. Transplantation, 2020, 104(7):1508-1518.
|
| 22 |
Andreassen AK, Andersson B, Gustafsson F, et al. Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: Three-year results from the randomized SCHEDULE study[J]. Am J Transplant, 2016, 16(4): 1238-1247.
|
| 23 |
Gustafsson F, Andreassen AK, Andersson B, et al. Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: Long-term follow-up from the randomized SCHEDULE study[J]. Transplantation, 2020, 104(1): 154-164.
|
| 24 |
Topilsky Y, Hasin T, Raichlin E, et al. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation[J]. Circulation, 2012, 125(5): 708-720.
|
| 25 |
Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study[J]. Circulation, 2001, 103(2): 192-195.
|
| 26 |
Zeng H, Chi H. mTOR signaling in the differentiation and function of regulatory and effector T cells[J]. Curr Opin Immunol, 2017, 46:103-111.
|
| 27 |
Bellumkonda L, Patel J. Recent advances in the role of mammalian target of rapamycin inhibitors on cardiac allograft vasculopathy[J]. Clin Transplant, 2020, 34(1): e13769.
|
| 28 |
Norum HM, Michelsen AE, Lekva T, et al. Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression[J]. Am J Transplant, 2019, 19(4): 1050-1060.
|
| 29 |
Mociornita AG, Adamson MB, Tumiati LC, et al. Effects of everolimus and HLA-G on cellular proliferation and neutrophil adhesion in an in vitro model of cardiac allograft vasculopathy[J]. Am J Transplant, 2018, 18(12): 3038-3044.
|
| 30 |
Asleh R, Prasad M, Briasoulis A, et al. Uric acid is an independent predictor of cardiac allograft vasculopathy after heart transplantation[J]. J Heart Lung Transplant, 2018, 37(9): 1083-1092.
|
| 31 |
Masetti M, Potena L, Nardozza M, et al. Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice[J]. Am J Transplant, 2013, 13(5):1217-1226.
|
| 32 |
Puttarajappa CM, Bernardo JF, Kellum JA. Renal complications following lung transplantation and heart transplantation[J]. Crit Care Clin, 2019, 35(1): 61-73.
|
| 33 |
Ma MKM, Yung S, Chan TM. mTOR inhibition and kidney diseases[J]. Transplantation, 2018, 102(2S Suppl 1):S32-S40.
|
| 34 |
Tholking G, Gillhaus NH, Schutte-Nutgen K, et al. Conversion to everolimus was beneficial and safe for fast and slow tacrolimus metabolizers after renal transplantation [J]. J Clin Med, 2020, 9(2): 328
|
| 35 |
Kelsh SE, Girgis R, Dickinson M, et al. Everolimus use for intolerance or failure of baseline immunosuppression in adult heart and lung transplantation[J]. Annals of Transplantation, 2018, 23:744-750.
|
| 36 |
Groetzner J, Kaczmarek I, Schulz U, et al. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure[J]. Transplantation, 2009, 87(5): 726-733.
|
| 37 |
Gonzalez-Vilchez F, Vazquez De Prada JA, Paniagua MJ, et al. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization？[J]. Int J Cardiol, 2014, 171(1): 15-23.
|
| 38 |
Gleissner CA, Doesch A, Ehlermann P, et al. Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy[J]. Am J Transplant, 2006, 6(11): 2750-2758.
|
| 39 |
Gude E, Gullestad L, Andreassen AK. Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all？[J]. Curr Opin Organ Transplant, 2017, 22(3): 198-206.
|
| 40 |
Tan L, Sato N, Shiraki A, et al. Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection[J]. Antiviral Res, 2019, 162:30-38.
|
| 31 |
Poglitsch M, Weichhart T, Hecking M, et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages[J]. Am J Transplant, 2012, 12(6): 1458-1468.
|
| 42 |
Bak S, Tischer S, Dragon A, et al. Selective effects of mTOR inhibitor sirolimus on naive and CMV-specific T cells extending its applicable range beyond immunosuppression[J]. Front Immunol, 2018, 9:2953.
|
| 43 |
Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy[J]. Int J Mol Sci, 2019, 20(3): 755.
|
| 44 |
Zuckermann A, Osorio-Jaramillo E, Aliabadi-Zuckermann AZ. mTOR inhibition and clinical transplantation: Heart[J]. Transplantation, 2018, 102(2S Suppl 1): S27-S29.
|
| 45 |
Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in adult solid organ transplantation[J]. Expert Opin Drug Saf, 2016, 15(3): 303-319.
|
| 46 |
Peterson TR, Sengupta SS, Harris TE, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway[J]. Cell, 2011, 146(3): 408-420.
|
| 47 |
Cybulski N, Polak P, Auwerx J, et al. mTOR complex 2 in adipose tissue negatively controls whole-body growth[J]. Proc Natl Acad Sci U S A, 2009, 106(24): 9902-9907.
|
| 48 |
Asleh R, Briasoulis A, Pereira NL, et al. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients[J]. J Heart Lung Transplant, 2018, 37(11): 1372-1380.
|
| 49 |
Verges B. mTOR and cardiovascular diseases: Diabetes mellitus[J]. Transplantation, 2018, 102(2S Suppl 1): S47-S49.
|
| 50 |
Kezic A, Popovic L, Lalic K. mTOR inhibitor therapy and metabolic consequences: where do we stand？[J]. Oxid Med Cell Longev, 2018:2640342.
|
| 51 |
Arriola Apelo SI, Neuman JC, Baar EL, et al. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system[J]. Aging Cell, 2016, 15(1): 28-38.
|
| 52 |
Asleh R, Alnsasra H, Lerman A, et al. Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients[J]. Am J Transplant, 2021, 21(2):626-635.
|
| 53 |
Anglicheau D, Pallet N, Rabant M, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction[J]. Kidney Int, 2006, 70(6): 1019-1025.
|
| 54 |
Grahammer F, Wanner N, Huber TB. mTOR controls kidney epithelia in health and disease[J]. Nephrol Dial Transplant, 2014, 29(Suppl 1): i9-i18.
|
| 55 |
Witkowsky O, Teuteberg J, Althouse AD, et al. Thrombotic events with proliferation signal inhibitorbased immunosuppression in cardiac transplantation[J]. J Heart Lung Transplant, 2019, 38(6): 619-626.
|
| 56 |
Steffel J, Latini RA, Akhmedov A, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design[J]. Circulation, 2005, 112(13): 2002-2011.
|
| 57 |
Willemsen AE, Grutters JC, Gerritsen WR, et al. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm[J]. Int J Cancer, 2016, 138(10): 2312-2321.
|
| 58 |
Lopez P, Kohler S, Dimri S. Interstitial lung disease associated with mTOR inhibitors in solid organ transplant recipients: Results from a large phase III clinical trial program of everolimus and review of the literature[J]. J Transplant, 2014:305931.
|
| 59 |
Budde K, Lehner F, Sommerer C, et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study[J]. Am J Transplant, 2015, 15(1): 119-128.
|
| 60 |
Oroszlan M, Bieri M, Ligeti N, et al. Proliferation signal inhibitor-induced decrease of vascular endothelial cadherin expression and increase of endothelial permeability in vitro are prevented by an anti-oxidant[J]. J Heart Lung Transplant, 2008, 27(12): 1311-1318.
|
| 61 |
Gonzalez-Vilchez F, Vazquez De Prada JA, Almenar L, et al. Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation[J]. J Heart Lung Transplant, 2012, 31(3): 288-295.
|
| 62 |
Pascual J, Marcen R, Ortuno J. Clinical experience with everolimus (Certican): optimizing dose and tolerability[J]. Transplantation, 2005, 79(9 Suppl): S80-S84.
|
| 63 |
Guba M, Pratschke J, Hugo C, et al. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation[J]. Transpl Int, 2012, 25(4): 416-423.
|
| 64 |
Lo Muzio L, Arena C, Troiano G, et al. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20，915 patients[J]. Oral Dis, 2018, 24(1-2): 144-171.
|
| 65 |
Karpe KM, Talaulikar GS, Walters GD. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients[J]. Cochrane Database Syst Rev, 2017, 7(7):CD006750.
|